drugset / Trial / NCT05492591

A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster

NCT05492591

Phase 2 Completed 50 enrolled Shanghai Institute Of Biological Products
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy, optimal dose and efficacy trend of multiple subcutaneous injections of peginterferon α1b in patients with herpes zoster, and provide support for phase III clinical trials.

Timeline

Start
2022-10-11
Primary completion
2023-07-22
Completion
2023-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon α1b Unknown 5 ug/kg Subcutaneous
Subject Peginterferon α1b Unknown 6 ug/kg Subcutaneous
Subject Peginterferon α1b Unknown 7 ug/kg Subcutaneous
Comparator Valacyclovir Unknown

Indications